The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis
Open accessThe DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Abstract
Recent advances in the understanding of brain cannabinoid receptor function have renewed interest in the association between cannabinoid compounds and psychosis. In a 3-day, double-blind, randomized, and counterbalanced study, the behavioral, cognitive, and endocrine effects of 0, 2.5, and 5 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC) were characterized in 22 healthy individuals, who had been exposed to cannabis but had never been diagnosed with a cannabis abuse disorder. Prospective safety data at 1, 3, and 6 months poststudy was also collected. Delta-9-THC (1) produced schizophrenia-like positive and negative symptoms; (2) altered perception; (3) increased anxiety; (4) produced euphoria; (5) disrupted immediate and delayed word recall, sparing recognition recall; (6) impaired performance on tests of distractibility, verbal fluency, and working memory (7) did not impair orientation; (8) increased plasma cortisol. These data indicate that Delta-9-THC produces a broad range of transient symptoms, behaviors, and cognitive deficits in healthy individuals that resemble some aspects of endogenous psychoses. These data warrant further study of whether brain cannabinoid receptor function contributes to the pathophysiology of psychotic disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is evidence to suggest a positive association between cannabis use and development of psychosis, in people susceptible to psychotic disorders.117–119”
From Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions (2024) · cites this paper as [119]
In the citing paper
“Randomised controlled trials in laboratory conditions provide evidence that delta-9-tetrahydrocannabinol (THC), the main active compound in cannabis, can induce transient psychotic-like experiences (1).”
From Association Between Cannabis and Psychosis: Epidemiologic Evidence (2016) · cites this paper as [1]
In the citing paper
“However, these experiences resolve within a few hours and rarely cause distress, in contrast to psychotic disorder where experiences are prolonged and impairment often substantial.”
From Association Between Cannabis and Psychosis: Epidemiologic Evidence (2016) · cites this paper as [1]
In the citing paper
“The experimental evidence showing that psychotic experiences occur during cannabis intoxication (1) indicates that cannabis has biological effects that could translate to chronic psychotic disorders.”
From Association Between Cannabis and Psychosis: Epidemiologic Evidence (2016) · cites this paper as [1]
Citations
Cites
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011 · cited 1×
“D-9-THC The psychotropic effects of D-9-THC are mediated by partial agonist effects at CB-1 receptors (CB-1R) where it has modest affinity (Ki¼ 35–80 nmol) and low intrinsic activity (Compton et al, 1992; Gerard et al, 1991; Howlett et al, 2002; Matsuda et al, 1990).”
BackgroundKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Self-citationInternational Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 1×
“…anterior cingulate cortex, and cerebellum (Egertova and Elphick, 2000; Egertova et al, 1998; Elphick and Egertova, 2001; Glass et al, 1997; Herkenham et al, 1991, 1990), brain regions that are relevant to both the known effects of cannabinoids and also regions that have been implicated in…”
BackgroundHerkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159 · cited 1×
“…anterior cingulate cortex, and cerebellum (Egertova and Elphick, 2000; Egertova et al, 1998; Elphick and Egertova, 2001; Glass et al, 1997; Herkenham et al, 1991, 1990), brain regions that are relevant to both the known effects of cannabinoids and also regions that have been implicated in…”
BackgroundRole of Endogenous Cannabinoids in Synaptic Signaling
FREUND, T. F., KATONA, I., & PIOMELLI, D. (2003) · Physiological Reviews · doi:10.1152/physrev.00004.2003 · Cited by 1,574
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002) · BMJ · doi:10.1136/bmj.325.7374.1212 · Cited by 1,399 · cited 1×
“…literature from pharmacological (Jones, 1971; Leweke et al, 2000, 1999b; McGuire et al, 1995), epidemiological (Andreasson et al, 1987, 1988, 1989; Arseneault et al, 2002; McGuire et al, 1995; Zammit et al, 2002), genetic (Ujike et al, 2002), neurochemical (Leweke et al, 1999a), and postmortem…”
BackgroundBorkowski, J. G., Benton, A. L., & Spreen, O. (1967) · Neuropsychologia · doi:10.1016/0028-3932(67)90015-2 · Cited by 1,302
Endocannabinoid Signaling in the Brain
Wilson, R. I., & Nicoll, R. A. (2002) · Science · doi:10.1126/science.1063545 · Cited by 1,260
Katona, I., Sperlágh, B., Sı́k, A., Käfalvi, A., Vizi, E. S., Mackie, K., & Freund, T. F. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-11-04544.1999 · Cited by 1,218
Research works printed but not linked: 6
- Belger A, Puce A, Krystal JH, Gore JC, Goldman-Rakic P, McCarthy G (1998). Dissociation of mnemonic perceptual processes during spatial nonspatial working memory using fMRI. Hum Brain Mapping 6: 14–32. · DOI · Paper page
- Gold MS (1991). Marijuana In: Miller eNS (ed). Comprehensive Handbook of Alcohol Drug Addiction. Marcel Decker: New York. pp 353–376.
- Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K et al (1999b). Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19: 4544–4558. · DOI · Paper page
- Moreau J (1973) In: Peters NGH (ed). Hashish Mental Illness. Raven Press: New York. pp 245.
- Moreau de Tours J (1973). Sobre el hachisch y la alienacion mental. Actas Luso-Espanolas Neurol Psiquiatr Cienc Afines 1: 477–484.
- Wall ME, Brine DR, Perez-Reyes M (1976). Metabolism of cannabinoids in man In: Braude MC, Szara S (eds). Pharmacology of Marihuana Vol 1, pp 536.
Cited by
Items 101–117 of 117
Hallak, J. E. C., Dursun, S. M., Bosi, D. C., de Macedo, L. R. H., Machado-de-Sousa, J. P., Abrão, J., Crippa, J. A. S., McGuire, P., Krystal, J. H., Baker, G. B., et al. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.002 · Cited by 83
“In humans, THC produces many signs and symptoms associated with schizophrenia (D'Souza et al., 2004), while CBD has few behavioral effects other than sedation at high doses (Hollister, 1973; Consroe et al., 1991; Zuardi et al., 1993).”
BackgroundSelf-citationBell, A. D., MacCallum, C., Margolese, S., Walsh, Z., Wright, P., Daeninck, P. J., Mandarino, E., Lacasse, G., Kaur Deol, J., de Freitas, L., et al. (2024) · Cannabis & Cannabinoid Research · doi:10.1089/can.2021.0156 · Cited by 78
“116 117–119 Although no defini-tive causal effects have been established, there are case reports of stroke, acute coronary syndrome, and cardiac arrhythmias associated with use of cannabis.”
BackgroundD'Souza, D. C., Singh, N., Elander, J., Carbuto, M., Pittman, B., de Haes, J. U., Sjogren, M., Peeters, P., Ranganathan, M., & Schipper, J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.295 · Cited by 66
“Psychotomimetic symptoms were measured using a version of the Positive and Negative Syndrome Scale (PANSS) (Kay et al, 1989) adapted for repeated measurements within a short time period (D’Souza et al, 2004).”
MethodSelf-citationRenard, J., Rushlow, W. J., & Laviolette, S. R. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00281 · Cited by 62
Cannabis and Anxiety: A Critical Review
Beletsky, A., Liu, C., Lochte, B., Samuel, N., & Grant, I. (2024) · Medical Cannabis and Cannabinoids · doi:10.1159/000534855 · Cited by 53
al'Absi, M., & Allen, A. M. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.687106 · Cited by 34
“Tolerance has also been found for other outcomes, including behavioral, subjective, and cognitive responses to cannabis (D’Souza et al., 2004, 2008; Ranganathan et al., 2009), which is consistent with preclinical evidence of tolerance (Murphy et al., 1998; González et al., 2005; Pagotto et al.,…”
ResultAthanassiou, M., Dumais, A., Gnanhoue, G., Abdel-Baki, A., Jutras-Aswad, D., & Potvin, S. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1942845 · Cited by 29
Effects of repeated adolescent exposure to cannabis smoke on cognitive outcomes in adulthood
Hernandez, C. M., Orsini, C. A., Blaes, S. L., Bizon, J. L., Febo, M., Bruijnzeel, A. W., & Setlow, B. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120965931 · Cited by 25
Feingold, D., Rehm, J., Factor, H., Redler, A., & Lev‐Ran, S. (2018) · Depression and Anxiety · doi:10.1002/da.22735 · Cited by 24
“The use of high-potency cannabis has been previously associated with elevated level of anxiety among healthy participants (D'Souza et al., 2004).”
BackgroundInfluentialRømer Thomsen, K., Callesen, M. B., & Feldstein Ewing, S. W. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.025 · Cited by 24
Withey, S. L., Kangas, B. D., Charles, S., Gumbert, A. B., Eisold, J. E., George, S. R., Bergman, J., & Madras, B. K. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108629 · Cited by 24
Cannabis and the increased incidence and persistence of psychosis
Hall, W., & Degenhardt, L. (2011) · BMJ · doi:10.1136/bmj.d719 · Cited by 23
The Changing Legal Landscape of Cannabis Use and Its Role in Youth-onset Psychosis
Wright, A., Cather, C., Gilman, J., & Evins, A. E. (2020) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2019.08.016 · Cited by 16
Mathai, D. S., Holst, M., Rodgman, C., Haile, C. N., Keller, J., Hussain, M. Z., Kosten, T. R., Newton, T. F., & Verrico, C. D. (2018) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.16120328 · Cited by 12
The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics
Ahmed, M., Boileau, I., Le Foll, B., Carvalho, A. F., & Kloiber, S. (2022) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2021-1926 · Cited by 11
Gunasekera, B., Davies, C., Blest-Hopley, G., Veronese, M., Ramsey, N. F., Bossong, M. G., Radua, J., Bhattacharyya, S., Pretzsch, C., McAlonan, G., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104801 · Cited by 10
Jones, H. J., Hammerton, G., McCloud, T., Hines, L. A., Wright, C., Gage, S. H., Holmans, P., Jones, P. B., Davey Smith, G., Linden, D. E. J., et al. (2022) · Psychological Medicine · doi:10.1017/s0033291720001798 · Cited by 9
Metadata
- Authors
- D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.-T., Braley, G., Gueorguieva, R., & Krystal, J. H.
- Affiliations
- Yale University (US)
- Nathan Kline Institute for Psychiatric Research (US)
- Venue
- Neuropsychopharmacology
- Published
- 2004-06-02
- Volume
- 29
- Issue
- 8
- Pages
- 1558-1572
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1996278273
- Cited by
- 1,024
- References
- 143
- Citations by year
- 2026: 28 · 2025: 24 · 2024: 40 · 2023: 45 · 2022: 66 · 2021: 64 · 2020: 91 · 2019: 50 · 2018: 57 · 2017: 61 · 2016: 58 · 2015: 49 · 2014: 55 · 2013: 36 · 2012: 55
- FWCI
- 12.75
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health (5k02aa000261-04)
- National Center for PTSD, U.S. Department of Veterans Affairs
- National Institute on Alcohol Abuse and Alcoholism (K02 AA00261-04)
- National Institute of Mental Health (R01 MH61019-02, MH 44866, MH61019-02, R01MH061019, P50 MH44866-15, P50MH044866)
- National Institute on Drug Abuse (R01DA012382, 1 DA12382-01)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Keywords
- delta-9-tetrahydrocannabinol, psychotomimetic effects, psychosis, schizophrenia-like symptoms, positive and negative symptoms, cognitive impairment, working memory, distractibility, verbal fluency, plasma cortisol, anxiety, euphoria, altered perception, cannabinoid receptors, cannabis use, healthy volunteers, drug safety
- MeSH terms
- Adult, Anxiety, Arousal, Attention, Behavior, Cognition, Dose-Response Relationship, Drug, Double-Blind Method, Female, Hallucinogens, Hemodynamics, Humans, Hydrocortisone, Injections, Intravenous, Male, Memory, Short-Term, Panic, Prolactin, Psychiatric Status Rating Scales, Psychometrics, Psychoses, Substance-Induced, Mental Recall, Speech, Dronabinol, Verbal Learning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.